866-997-4948(US-Canada Toll Free)

Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) - Pipeline Review, H1 2018

Published By :

Global Markets Direct

Published Date : Feb 2018

Category :

Pharmaceutical

No. of Pages : 51 Pages

Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) - Pipeline Review, H1 2018

Summary

According to the recently published report 'Mitogen Activated Protein Kinase 1 - Pipeline Review, H1 2018'; Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) pipeline Target constitutes close to 11 molecules. Out of which approximately 11 molecules are developed by Companies.

Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) - Mitogen-activated protein kinase 14 also called p38-alpha is an enzyme belongs to p38 MAPK family. p38-alpha MAPK play an important role in the cascades of cellular responses evoked by extracellular stimuli such as proinflammatory cytokines or physical stress leading to direct activation of transcription factors. p38-alpha MAPK is expressed in many cell types. p38-alpha MAPK is implicated in cell apoptosis, proliferation, differentiation, migration, mRNA stability, and inflammatory response in different cell types through variety of different target molecules.

The report 'Mitogen Activated Protein Kinase 1 - Pipeline Review, H1 2018' outlays comprehensive information on the Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 1 and 4 respectively. Report covers products from therapy areas Oncology and Musculoskeletal Disorders which include indications Colorectal Cancer, Non-Small Cell Lung Cancer, Metastatic Melanoma, Pancreatic Ductal Adenocarcinoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Colon Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Lung Cancer, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Colorectal Cancer, Myelodysplastic Syndrome, Osteoarthritis, Pancreatic Cancer, Solid Tumor and Uveal Melanoma.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24)
- The report reviews Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) targeted therapeutics and enlists all their major and minor projects
- The report assesses Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) - Overview
Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) - Companies Involved in Therapeutics Development
Aeterna Zentaris Inc
AGV Discovery SAS
Asana BioSciences LLC
Eli Lilly and Co
Kalyra Pharmaceuticals Inc
Kura Oncology Inc
Merck & Co Inc
Merck KGaA
Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) - Drug Profiles
ASN-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CB-745 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JRP-890 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KO-947 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3214996 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-8353 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Aurora B Kinase and ERK2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ERK1 and ERK2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ERK1 and ERK2 for Pancreatic Ductal Adenocarcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sprifermin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ulixertinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) - Dormant Products
Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) - Discontinued Products
Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) - Product Development Milestones
Featured News & Press Releases
Jan 03, 2018: Asana BioSciences Announces Acceptance of IND Application for Its Oral ERK1/2 Inhibitor
Dec 15, 2017: First-in-class ERK1/2 Inhibitor Safe, Shows Early Efficacy in Patients With Advanced Solid Tumors
Nov 04, 2017: Merck KGaA, Darmstadt, Germany Presents Late Breaking Clinical Data from Phase II Trial of Sprifermin for Osteoarthritis Disease Modification
Oct 24, 2017: Asana BioSciences to Present Update On Lead Molecule ASN-007 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Oct 20, 2017: Merck Presents New Data on Sprifermin at 2017 ACR/ARHP Annual Meeting
Oct 03, 2017: First-in-class ERK inhibitor ulixertinib (BVD-523) shows promise in preclinical cancer models
Jun 21, 2017: NovellusDx Announced the Completion of the First Phase of an In-vitro Study of BioMed Valley Discoveries' BVD523
May 26, 2017: BioMed Valley Discoveries announces presentation of early clinical activity of first-in-class cancer therapy ulixertinib at 2017 ASCO annual meeting
Apr 19, 2017: Kura Oncology Granted U.S. Patent for Clinical-Stage ERK Inhibitor, KO-947
Apr 07, 2017: Kura Oncology Doses First Patient in Phase 1 Trial of ERK Inhibitor KO-947
Apr 05, 2017: Kura Oncology Presents Preclinical Data Demonstrating Significant Anti-Tumor Activity of KO-947
Mar 29, 2017: Kura Oncology to Present Preclinical Data on KO-947 at AACR Annual Meeting 2017
Jan 04, 2017: Kura Oncology Receives FDA Clearance to Proceed with Clinical Trial for ERK Inhibitor KO-947
Dec 01, 2016: Kura Oncology Presents Preclinical Data on KO-947 the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Nov 15, 2016: Kura Oncology to Present Preclinical Data on Pipeline Programs at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Aeterna Zentaris Inc, H1 2018
Pipeline by AGV Discovery SAS, H1 2018
Pipeline by Asana BioSciences LLC, H1 2018
Pipeline by Eli Lilly and Co, H1 2018
Pipeline by Kalyra Pharmaceuticals Inc, H1 2018
Pipeline by Kura Oncology Inc, H1 2018
Pipeline by Merck & Co Inc, H1 2018
Pipeline by Merck KGaA, H1 2018
Dormant Projects, H1 2018
Discontinued Products, H1 2018

List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *